Trial reportDrug design, development and therapy2026
Coenzyme Q10 Impact on Ovarian Reserve Measures and the Intra-Cytoplasmic Sperm Injection (ICSI) Outcomes in Women with Poor Ovarian Response: A Randomized Controlled Study.
Trial report in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06405204 (The Effect of Myo-inositol, Melatonin and Co-enzyme q10 on Ovarian Reserve Parameters and Intra-cytoplasmic Sperm Injection Outcomes in Patient With Poor Ovarian Reserve), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of Myo-inositol, Melatonin and Co-enzyme q10 on Ovarian Reserve Parameters and Intra-cytoplasmic Sperm Injection Outcomes in Patient With Poor Ovarian Reserve: an Open Label Randomized Clinical Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Poor ovarian response (POR) is a serious problem that decreases the effectiveness of conventional ovarian stimulation. Its concern is elevated production of reactive oxygen species, causing DNA destruction and mitochondrial malfunction, which contributes to the decline in oocyte quality. Objective of the Study: This trial aimed to identify the impact of Coenzyme Q10 as an antioxidant on ovarian reserve markers and Intra-cytoplasmic sperm injection results in poor ovarian responders. Methods: A prospective controlled study included 100 patients classified as poor ovarian responders according to the Bologna criteria. The patients were randomly allocated to two groups. Fifty participants in group A were administrated Coenzyme Q10 plus folic acid for one month prior to the ICSI cycle and through the ICSI cycle. Fifty patients in group B were administrated folic acid only for a similar duration. The primary outcome measured was the count of oocytes obtained. The chemical pregnancy rate was considered a secondary outcome. Results: The baseline features were equivalent among the groups. CoQ10 markedly improved the oocyte count and peak E2 (p <0.001). Higher levels of antral follicle count at the start of the induction were observed in the treated group (p= 0.001). Endometrial thickness was greater in the CoQ10 group than in the control group (p=0.004). Significant differences were found in the count of embryos transferred and the percentage of women who underwent no embryo transfer (p=0.011). No substantial variations were detected in the gonadotropin doses, induction days, or progesterone levels among the two groups. The chemical and clinical pregnancy rates and completed cycles were equivalent between the two groups, with insignificant differences. Conclusion: CoQ10 promotes ovarian response to conventional induction and has a beneficial effect on ovarian reserve and embryological measures in poor responders. Despite this, additional investigations are essential to determine its influence on pregnancy rates. Clinical Trial ID: NCT06405204.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.